Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SRNE save search
Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
Published: 2021-08-11 (Crawled : 13:00) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 0.0%
H: 1.36%
C: 0.68%
DYAI 4 | $1.52 2.01% 3.2K
|
Health Technology
|
| O: 20.33%
H: 28.7%
C: 22.22%
covid vaccine license technology
Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
Published: 2021-08-11 (Crawled : 13:15) - biospace.com/
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 0.0%
H: 1.36%
C: 0.68%
DYAI 4 | $1.52 2.01% 3.2K
|
Health Technology
|
| O: 20.33%
H: 28.7%
C: 22.22%
covid vaccine license technology
Update to 01/26/21 COVI-MSC™ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells
Published: 2021-01-31 (Crawled : 23:00) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 13.35%
H: 7.28%
C: 1.95%
stem cell
Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case
Published: 2023-02-21 (Crawled : 00:00) - prnewswire.com
SCLX | $0.8407 -13.92% -16.18% 1.7M
|
|
| O: -1.9%
H: 5.12%
C: 3.74%
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 11.57%
H: 10.12%
C: -28.53%
approval
Sorrento Receives Licensure From the State of California for Clinical Testing Laboratory (CLIA) Allowing for Clinical Sample Testing
Published: 2020-12-09 (Crawled : 01:08) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 10.51%
H: 2.29%
C: -5.96%
test
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in Healthy Volunteers and in Newly Diagnosed COVID-19 Patients
Published: 2020-12-09 (Crawled : 14:05) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 10.51%
H: 2.29%
C: -5.96%
covid fda clearance fda trial phase 3 phase 1 phase 2 clearance
Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President
Published: 2022-05-31 (Crawled : 12:20) - biospace.com/
ZNTL | $11.76 -6.44% -6.89% 760K
|
Health Technology
|
| O: 9.05%
H: 0.0%
C: -1.39%
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 8.5%
H: 0.6%
C: -1.2%
Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes
Published: 2022-06-03 (Crawled : 13:20) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 8.18%
H: 2.33%
C: -0.58%
repurchase
Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster
Published: 2022-06-03 (Crawled : 15:20) - biospace.com/
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 8.18%
H: 2.33%
C: -0.58%
sti-1558 covid-19 treatment therapeutics
Scilex Holding Company Announces that Sorrento Therapeutics, Inc.’s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock
Published: 2023-06-15 (Crawled : 13:00) - globenewswire.com
SCLX | $0.8407 -13.92% -16.18% 1.7M
|
|
| O: 7.38%
H: 3.49%
C: -2.75%
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 1.67%
H: 1.67%
C: -1.97%
order
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
Published: 2023-11-17 (Crawled : 17:00) - biospace.com/
VRPX | $3.19 0.95% 0.94% 4.7K
|
|
| O: 6.92%
H: 0.0%
C: -7.88%
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 0.0%
H: 14.29%
C: 3.05%
nasdaq virpax pharmaceuticals
Sorrento to Present Data Demonstrating STI-2020 Preserves Binding Against UK B.1.1.7 SARS-CoV-2 Mutated Spike Protein
Published: 2021-01-19 (Crawled : 23:00) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 6.57%
H: 5.57%
C: -0.2%
sars-cov-2
Sorrento Receives Orders of COVISTIX for Commercial Launch in Brazil
Published: 2021-12-06 (Crawled : 20:00) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 6.57%
H: 14.77%
C: 11.21%
order brazil commercialization
Sorrento Therapeutics’ Clinical Laboratory Receives Accreditation From the College of American Pathologists
Published: 2021-12-07 (Crawled : 19:00) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 6.57%
H: 14.77%
C: 11.21%
therapeutics
Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise
Published: 2021-06-02 (Crawled : 13:15) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 6.54%
H: 6.33%
C: 3.69%
acquisition
Sorrento Announces It Has Submitted An Emergency Use Authorization (EUA) Application to the FDA for COVI-STIX™ Rapid Test for the Detection of SARS-CoV-2 Viral Antigen
Published: 2020-12-22 (Crawled : 00:02) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 6.51%
H: 15.47%
C: 11.31%
fda merge test authorized sars-cov-2 application emergency use authorization
Nutriband Inc. to Manufacture Fleur Marché-branded Wellness Patches Under Exclusive Agreement
Published: 2022-10-27 (Crawled : 11:00) - nutriband.com
NTRB | $3.56 -8.76% 3.2K
|
Manufacturing
|
| O: 8.17%
H: 0.0%
C: -1.33%
JWN | $19.26 -2.33% -0.05% 2.4M
|
Retail Trade
|
| O: 1.25%
H: 1.66%
C: -2.27%
URBN | $39.18 -0.46% 800K
|
Retail Trade
|
| O: 0.94%
H: 1.54%
C: -0.2%
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 1.26%
H: 0.62%
C: -4.97%
BBBY | $0.0751 -27.09% -47.14% 190M
|
Retail Trade
|
| O: 5.95%
H: 5.14%
C: -3.49%
agreement
Dr. Henry Ji to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 20, 2021
Published: 2021-01-19 (Crawled : 08:00) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 5.16%
H: 7.91%
C: -5.61%
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (LBP)
Published: 2022-08-31 (Crawled : 04:00) - globenewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 5.15%
H: 2.94%
C: 0.49%
sp-103 ztlido treatment fda designation back granted fast track designation
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute LBP
Published: 2022-08-31 (Crawled : 08:00) - biospace.com/
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: 5.15%
H: 2.94%
C: 0.49%
sp-103 ztlido treatment fda designation granted fast track designation
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
ILAG | $0.51 6.03% 29.06% 430K
|
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.